Prospects for Targeting PD-1 and PD-L1 in Various Tumor Types

被引：0

作者：

Kim, Joseph W. ^{[1
]}

Eder, Joseph Paul ^{[1
]}

机构：

[1] Yale Univ, Sch Med, Yale Comprehens Canc Ctr, Dept Med, New Haven, CT 06520 USA

来源：

ONCOLOGY-NEW YORK | 2014年 / 28卷

关键词：

RENAL-CELL CARCINOMA; CANCER; SAFETY; MELANOMA; SURVIVAL; ANTIBODY; IPILIMUMAB; ANTI-PD-1; EXPRESSION; REGRESSION;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoints, such as programmed death ligand 1 (PD-L1) or its receptor, programmed death 1 (PD-1), appear to be Achilles' heels for multiple tumor types. PD-L1 not only provides immune escape for tumor cells but also turns on the apoptosis switch on activated T cells. Therapies that block this interaction have demonstrated promising clinical activity in several tumor types. In this review, we will discuss the current status of several anti-PD-1 and anti-PD-L1 antibodies in clinical development and their direction for the future.

引用

页码：15 / 28

页数：14

共 50 条

[41] Lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1/PD-L1 blockade therapy-resistant tumor
Oh, Wonkyung
Kim, Alyssa Min Jung
Dhawan, Deepika
Knapp, Deborah W.
Lim, Seung-Oe
MOLECULAR THERAPY, 2025, 33 (02)
[42] Tumor Necrosis Correlates with PD-L1 and PD-1 Expression in Lung Adenocarcinoma
Moldvay, J.
Teglasi, V.
Pipek, O.
Rojko, L.
Glasz, T.
Vagvolgyi, A.
Kovalszky, I.
Gyulai, M.
Lohinai, Z.
Raso, E.
Timar, J.
Dome, B.
Szallasi, Z.
Reiniger, L.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S505 - S505
[43] PD-1/PD-L1 axis importance and tumor microenvironment immune cells
Lotfinejad, Parisa
Kazemi, Tohid
Mokhtarzadeh, Ahad
Shanehbandi, Dariush
Niaragh, Farhad Jadidi
Safaei, Sahar
Asadi, Milad
Baradaran, Behzad
LIFE SCIENCES, 2020, 259
[44] Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma
Wei, Hangzhi
Wu, Fahong
Mao, Yudong
Zhang, Youcheng
Leng, Guangxian
Wang, Jia
Zhang, Wei
Wang, Tianwei
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (04) : 331 - 345
[45] Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
Pu, Yunzhou
Ji, Qing
FRONTIERS IN IMMUNOLOGY, 2022, 13
[46] Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma
Reiniger, Lilla
Teglasi, Vanda
Pipek, Orsolya
Rojko, Livia
Glasz, Tibor
Vagvoelgyi, Attila
Kovalszky, Ilona
Gyulai, Marton
Lohinai, Zoltan
Raso, Erzsebet
Timar, Jozsef
Dome, Balazs
Szallasi, Zoltan
Moldvay, Judit
ACTA ONCOLOGICA, 2019, 58 (08) : 1087 - 1094
[47] PD-1/PD-L1 immune checkpoints: Tumor vs atherosclerotic progression
Liang, Yamin
Li, Lu
Chen, Yanmei
Xiao, Jinyan
Wei, Dangheng
CLINICA CHIMICA ACTA, 2021, 519 : 70 - 75
[48] Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model
Salehi, Shima
Ghaderi, Hajarossadat
Habibi-Anbouhi, Mahdi
Shoari, Alireza
Eskafi, Ayda Hassanzadeh
Sabouri, Alireza
Hosseininejad-Chafi, Mohammad
Ardalan, Arghavan Ashja
Ramezani, Behzad
Kazemi-Lomedasht, Fatemeh
Behdani, Mahdi
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2022, 21 (01):
[49] Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
Lipson, Evan J.
Lilo, Mohammed T.
Ogurtsova, Aleksandra
Esandrio, Jessica
Xu, Haiying
Brothers, Patricia
Schollenberger, Megan
Sharfman, William H.
Taube, Janis M.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[50] FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Dahan, Rony
Sega, Emanuela
Engelhardt, John
Selby, Mark
Korman, Alan J.
Ravetch, Jeffrey V.
CANCER CELL, 2015, 28 (03) : 285 - 295

← 1 2 3 4 5 →